Search

Search Constraints

You searched for: Author/Creator Castel, Victoria

Search Results

3. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Issue 4 (April 2017)

6. Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Issue 30 (20th October 2021)

7. Image‐defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy‐induced variation, and impact on surgical outcomes. Issue 11 (25th April 2017)

8. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Issue 12 (December 2018)

9. Intratumoral immunosuppression profiles in 11q‐deleted neuroblastomas provide new potential therapeutic targets. Issue 2 (19th January 2021)